BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 14519411)

  • 1. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia.
    Singh A; Naidu PS; Kulkarni SK
    Eur J Pharmacol; 2003 Sep; 477(2):87-94. PubMed ID: 14519411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia.
    Naidu PS; Singh A; Kulkarni SK
    Neuropharmacology; 2003 Jun; 44(8):1100-6. PubMed ID: 12763102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1130-8. PubMed ID: 17513028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms.
    Naidu PS; Singh A; Kulkarni SK
    Br J Pharmacol; 2002 May; 136(2):193-200. PubMed ID: 12010767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of haloperidol-induced orofacial dyskinesia by quercetin, a bioflavonoid.
    Naidu PS; Singh A; Kulkarni SK
    Psychopharmacology (Berl); 2003 Jun; 167(4):418-23. PubMed ID: 12669184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements.
    Naidu PS; Kulkarni SK
    Eur J Pharmacol; 2001 Sep; 428(1):81-6. PubMed ID: 11779040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Eur J Pharmacol; 2006 Dec; 552(1-3):55-66. PubMed ID: 17064683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of haloperidol-induced orofacial dyskinesia by Murraya koenigii leaves in experimental animals.
    Patil R; Hiray Y; Shinde S; Langade P
    Pharm Biol; 2012 Jun; 50(6):691-7. PubMed ID: 22136413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats.
    Dhingra D; Goswami S; Gahalain N
    Nutr Neurosci; 2018 Nov; 21(9):667-675. PubMed ID: 28641484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Withania somnifera root extract on reserpine-induced orofacial dyskinesia and cognitive dysfunction.
    Naidu PS; Singh A; Kulkarni SK
    Phytother Res; 2006 Feb; 20(2):140-6. PubMed ID: 16444668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Korean ginseng extract attenuates reserpine-induced orofacial dyskinesia and improves cognitive dysfunction in rats.
    Sanghavi CR; Barhate SA; Mahajan MS; Mohan M; Kasture SB
    Nat Prod Res; 2011 Apr; 25(7):704-15. PubMed ID: 20628966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of reserpine-induced orofacial dyskinesia and cognitive dysfunction by quercetin.
    Naidu PS; Singh A; Kulkarni SK
    Pharmacology; 2004 Feb; 70(2):59-67. PubMed ID: 14685008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulatory effect of neurosteroids in haloperidol-induced vacuous chewing movements and related behaviors.
    Bishnoi M; Chopra K; Kulkarni SK
    Psychopharmacology (Berl); 2008 Feb; 196(2):243-54. PubMed ID: 17955214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible mechanism of action in melatonin attenuation of haloperidol-induced orofacial dyskinesia.
    Naidu PS; Singh A; Kaur P; Sandhir R; Kulkarni SK
    Pharmacol Biochem Behav; 2003 Feb; 74(3):641-8. PubMed ID: 12543230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacology; 2007; 79(3):171-83. PubMed ID: 17377417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Withania somnifera root extract on haloperidol-induced orofacial dyskinesia: possible mechanisms of action.
    Naidu PS; Singh A; Kulkarni SK
    J Med Food; 2003; 6(2):107-14. PubMed ID: 12935321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation.
    Datta S; Jamwal S; Deshmukh R; Kumar P
    Eur J Pharmacol; 2016 Jan; 771():229-35. PubMed ID: 26712377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. U-74500A (lazaroid), a 21-aminosteroid attenuates neuroleptic-induced orofacial dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Methods Find Exp Clin Pharmacol; 2007 Nov; 29(9):601-5. PubMed ID: 18193111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.